Lexeo's LX2006 shows sustained neurological benefit in Friedreich ataxia trial through 36 months
LXEO•Lexeo Therapeutics said LX2006 showed sustained or deepening cardiac and neurological benefits through 36 months in a Phase 1/2 Friedreich ataxia trial. The company will present new interim results at ICAR from November 10-13, 2026.
1. Interim trial results
Treated participants showed significantly improved neurological outcomes compared with a matched natural history control group. Lexeo Therapeutics plans to present new interim Phase 1/2 results for LX2006 at ICAR from November 10-13, 2026.
